Gengos Andrew 4
4 · Terns Pharmaceuticals, Inc. · Filed Feb 25, 2025
Insider Transaction Report
Form 4
Gengos Andrew
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-02-24+750,000→ 750,000 totalExercise: $3.73Exp: 2035-02-23→ Common Stock (750,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest on the first anniversary measured from February 24, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.